20 results
8-K
EX-10.1
HROW
Harrow Inc
14 Dec 22
Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to
6:45am
and warranties of Novartis contained in this Agreement shall be true and correct as of the Closing (disregarding all materiality and “Material Adverse Effect … without any materiality qualification) or in all respects (in the case of any representation or warranty containing any materiality qualification
8-K
EX-10.1
584mw 8e5y7ts
2 Sep 21
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10
qds4cqq3
3 Apr 20
Entry into a Material Definitive Agreement
7:30am
8-K
EX-10.1
lxzqln
29 May 19
Harrow Health Announces Renegotiated Debt Facility with SWK Holdings
7:30am
8-K
EX-10.1
xddgnjukrfsijoq4
23 Dec 16
Imprimis Pharmaceuticals Announces $9.8 Million Private Placement of Units
12:00am
8-K
0q6o9tx0 41o
6 Jan 15
Completion of Acquisition or Disposition of Assets
12:00am
8-K
bvc1229 b27u7
2 Dec 14
Imprimis Pharmaceuticals Signs Agreement to Acquire
12:00am
8-K
EX-2.1
bcwmnj
2 Dec 14
Imprimis Pharmaceuticals Signs Agreement to Acquire
12:00am
8-K
fswqkx28nmx43otigkj
3 Apr 14
Completion of Acquisition or Disposition of Assets
12:00am
8-K
EX-2.1
lzvrj737zrnn9
11 Feb 14
Empowering Company to Make and Distribute its Patent-Pending Proprietary Formulations
12:00am
8-K
syke2q9o
11 Feb 14
Empowering Company to Make and Distribute its Patent-Pending Proprietary Formulations
12:00am
8-K
EX-2.1
a48nsv
27 Jun 11
Entry into a Material Definitive Agreement
12:00am
- Prev
- 1
- Next